Summit's Antibiotic Spares The Microbiome And Spoils The C Diff Rods
This article was originally published in Scrip
Executive Summary
Summit Therapeutics' novel narrow-spectrum antibiotic ridinilazole (SMT19969) is highly effective in reducing recurrence in Clostridium difficile infections (CDI), and could address a major unmet need in the treatment of the disease, suggest Phase II data due to be presented at the ECCMID meeting in Amsterdam in April.
You may also be interested in...
Merck & Co Expands C Diff Franchise With US Zinplava Approval
Merck & Co is planning a first-quarter 2017 launch of Zinplava, its novel therapy for use in Clostridium difficile infection, following a US FDA approval, strengthening the company’s leading position in an infectious disease with great unmet need.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.